DOXERCALCIFEROL by Novartis is 2 analog that requires metabolic activation to form the active 1α,25-(oh) 2 d 2 metabolite, which binds to the vitamin d receptor (vdr) to result in the selective activation of vitamin d responsive pathways. Approved for secondary hyperparathyroidism in adult patients with stage 3, stage 4 chronic kidney disease (ckd). First approved in 2014.
Drug data last refreshed 20h ago
2 analog that requires metabolic activation to form the active 1α,25-(OH) 2 D 2 metabolite, which binds to the vitamin D receptor (VDR) to result in the selective activation of vitamin D responsive pathways. Vitamin D and doxercalciferol have been shown to reduce PTH levels by inhibiting PTH…
Worked on DOXERCALCIFEROL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients
Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer